LJ Tan, MS, PhD - RSV Vaccines in Older Adults: Emerging Prevention Strategies

episode

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Iran's President Addresses the UN General Assembly 3 min · 23 Sep 2026 · Fox News Hourly Update

Matheson on Guerrero Jr.'s contract comments, his season performance and the optics of the statement 10 min · 23 Sep 2026 · OverDrive

Vladdy's Controversial Contract Comments 24 min · 23 Sep 2026 · Blair & Barker

Dreger on Babcock's role with the Oilers, Hiller leading the Maple Leafs and Fantilli's contract value 19 min · 23 Sep 2026 · OverDrive

Evening Wire: President Xi Arrives In Washington & Category 5 Hurricane Approaches Mexico | 9.23.26 10 min · 23 Sep 2026 · Morning Wire

How Your Money Trauma Becomes Your Kid's 48 min · 23 Sep 2026 · Money Rehab with Nicole Lapin

Report any issue

Source

Recorded28 Oct 2022

Publisherc.answersincme.com ↗

Handlerec:13096861

Show notes

Please visit answersincme.com/JUK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in immunology discusses the burden of respiratory syncytial virus (RSV) in older adults and the clinical impact of late-stage emerging RSV vaccines. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for vaccines to prevent respiratory syncytial virus (RSV) in older adults; Identify factors contributing to poor RSV outcomes in older adults; and Describe the clinical significance of available data for late-stage investigational RSV vaccines in older adults.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in